US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA). http://www.pharmatimes.com/news/fda_advisors_back_lillyincytes_rheumatoid_arthritis_drug_1233030
ST. PAUL, Minn., Oct. 17, 2017 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime) show commercially insured members with rheumatoid arthritis (RA) had 3.5 times higher total cost of care than members without RA. But optimizing conventional disease… https://www.prnewswire.com/news-releases/prime-therapeutics-studies-examine-rheumatoid-arthritis-therapies-and-total-cost-300536842.html
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx (secukinumab) evidencing its long term skin clearance benefits and safety profile in the treatment of psoriasis.
read more http://www.pharmafile.com/news/515108/novartis-cosentyx-proves-long-term-efficacy-psoriasis-skin-clearance
Bristol─Myers Squibb Company announced that the European Commission (EC) has approved Orencia alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult http://pharmabiz.com/ArticleDetails.aspx?aid=103403&sid=2
Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early lead development. http://www.worldpharmanews.com/amgen/4025-amgen-and-array-biopharma-announce-preclinical-license-and-collaboration-agreement-in-inflammation
New label shows Cosentyx is superior to J&J’s rival in long-term.
The post Novartis’ psoriasis drug gets label boost appeared first on Pharmaphorum. https://pharmaphorum.com/news/novartis-cosentyx-gets-label-boost/
Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.
read more http://www.pharmafile.com/news/514503/eli-lilly-arthritis-drug-outperforms-humira-and-receives-nice-backing
Pharma firm’s ‘Behind The Smile’ initiative coincides with RA awareness week http://www.pmlive.com/pharma_news/lilly_and_nras_launch_arthritis_awareness_film_campaign_1196283
(Reuters) – U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.
The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis (RA) in patients who have not responded to prior therapy.
read more http://www.pharmafile.com/news/514154/sanofi-and-regeneron-score-fda-approval-arthritis